サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1788339

SGLT2阻害薬の世界市場

SGLT2 Inhibitors

出版日
ページ情報
英文 177 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
SGLT2阻害薬の世界市場
出版日: 2025年08月12日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 177 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

SGLT2阻害薬の世界市場は2030年までに295億米ドルに達する見込み

2024年に184億米ドルと推定されたSGLT2阻害薬の世界市場は、分析期間2024-2030年にCAGR 8.1％で成長し、2030年には295億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである2型糖尿病は、CAGR 8.6%を記録し、分析期間終了時には155億米ドルに達すると予測されます。心血管セグメントの成長率は、分析期間中CAGR 8.8%と推定されます。

米国市場は48億米ドルと推定、中国はCAGR 7.9％で成長予測

米国のSGLT2阻害薬市場は、2024年に48億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR7.9％を引きずる形で、2030年までに47億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.5％と6.8％と予測されています。欧州では、ドイツがCAGR約6.5％で成長すると予測されています。

世界のSGLT2阻害薬市場- 主要動向と促進要因のまとめ

治療範囲の拡大がSGLT2阻害薬の市場情勢を変える？

SGLT2阻害薬の世界市場は、2型糖尿病の血糖コントロールという当初の焦点をはるかに超えて、大きな変貌を遂げつつあります。新しいクラスの抗糖尿病薬として始まったこの薬剤は、今や心臓・腎臓・代謝ケアの基礎治療へと発展しています。ここ数年の臨床試験では、エンパグリフロジン、ダパグリフロジン、カナグリフロジンなどのSGLT2阻害薬が、血糖降下作用とは別に心血管保護作用や腎保護作用を示すことが一貫して証明されています。その結果、これらの薬剤は2型糖尿病だけでなく、駆出率低下型心不全（HFrEF）、慢性腎臓病（CKD）、さらに最近では駆出率維持型心不全（HFpEF）にも処方されるようになってきています。世界中の規制機関は、承認された適応症を拡大することでこれに対応し、これらの治療法の対象となる患者層を劇的に広げています。この変化は、内分泌専門医、循環器専門医、腎臓専門医が共有の薬理学的ツールを用いて患者を共同管理し始めるという、市場の重要な変曲点を示しています。SGLT2阻害薬の多疾患治療薬としての位置づけの変更は、その臨床的価値、ヘルスケアシステムとの関連性、長期的な市場持続可能性を著しく高めています。

実世界でのエビデンスとガイドラインへの盛り込みは、主流への採用を促進できるか？

SGLT2阻害薬が広く採用される最も強力な原動力の一つは、確固とした実臨床エビデンスと世界の臨床ガイドラインからの大きな支持です。米国糖尿病学会（ADA）、欧州心臓病学会（ESC）、腎臓病学会（KDIS）などの組織です。Improving Global Outcomes（KDIGO）、American College of Cardiology（ACC）などの団体が、グルコースコントロールだけでなく、糖尿病のない患者であっても、心不全やCKDの第一選択薬として、SGLT2阻害薬を急速に治療プロトコールに取り入れています。このように、専門分野を超えて受け入れられることで、処方者の信頼が高まり、より早い開始と、患者プロファイルを超えた幅広い使用につながっています。さらに、大規模なアウトカム研究によって、心不全による入院を減らし、腎臓病の進行を遅らせ、心血管死亡率を低下させるという薬剤クラスの利点が引き続き強化されています。これらの知見は、特にバリュー・ベースのヘルスケア・モデルを導入している市場において、支払者やフォーミュラリー委員会を説得し、償還を拡大させるのに役立っています。市販後調査データと患者登録の蓄積は、薬剤の安全性プロファイルをさらに検証し、糖尿病性ケトアシドーシスや泌尿生殖器感染症などの副作用に関する懸念を払拭するのに役立っています。こうしたエビデンスに基づく強固な基盤が、SGLT2阻害薬を近年最も急速に採用されている治療薬クラスのひとつにしています。

市場力学と競合の拡大がSGLT2ベースの治療薬のイノベーションを促進している？

第一世代のSGLT2阻害薬の商業的成功は、製薬会社各社がこの薬効クラスの臨床的および市場的フットプリントを拡大しようと競い合う、研究開発および市場競争の波に火をつけた。DPP-4阻害薬やGLP-1受容体作動薬と組み合わせたSGLT2阻害薬のような併用療法の出現は、糖尿病と代謝異常の統合的管理に新たな道を開いています。同時に、二重または三重の阻害活性を持つ次世代分子（例えば、SGLT1/SGLT2阻害薬）が、有効性を高め、治療標的を拡大するために開発されています。各社はまた、患者の服薬アドヒアランスと利便性を向上させるため、新規のデリバリー形式、徐放性製剤、共配合錠剤を模索しています。特にジェネリック医薬品やバイオシミラー医薬品では、主要な特許が期限切れを迎え、この分野に参入する企業が増えるにつれ、競合他社との差別化が極めて重要になってきています。さらに、戦略的パートナーシップ、ライセンシング契約、共同マーケティング契約も増加傾向にあり、各社は市場でのポジショニングと地域アクセスの強化を図っています。特にアジア太平洋、ラテンアメリカ、中東など、十分なサービスを受けていない市場への地理的拡大も重要な戦略であり、慢性疾患の流行に対する意識の高まりと診断インフラの改善によって可能となっています。競争分野がより洗練されるにつれて、イノベーションと市場の俊敏性がSGLT2阻害薬カテゴリーの次の成長段階を定義しています。

SGLT2阻害薬市場の急成長の原動力は？

SGLT2阻害薬市場の成長は、進化する臨床ガイドライン、適応症の拡大、ヘルスケアインフラの動向に直結するいくつかの要因によって牽引されています。第一に、グルコース中心の処方から心血管と腎臓の保護に焦点を当てた幅広い処方へのシフトにより、対象となる患者数が大幅に増加しています。第二に、国際的なガイドラインの強力な支持により、複数の専門分野にわたる採用が推進され、内分泌専門医だけでなく、循環器専門医や腎臓専門医にとっても、これらの薬剤が頼りになる治療法となっています。第三に、2型糖尿病、心不全、慢性腎臓病の世界の負担の増大により、多臓器保護と長期予後をもたらす治療法の必要性が拡大しています。第四に、医薬品の技術革新が、併用療法、適応拡大、次世代分子によって、薬剤クラスのライフサイクルを延長していることです。第五に、医師の意識向上と教育プログラムにより、より早期の治療開始とアドヒアランスの向上が促されています。第6に、高リスク患者に対するSGLT2阻害薬の償還に対する支払者の意欲が、特にバリュー・ベース・ケア・モデルを導入している地域において、アクセスを支援しています。第七に、デジタルヘルスの統合により、治療結果のモニタリングと長期的な追跡が可能になり、実際の価値を実証するのに役立っています。最後に、予防効果が証明された1日1回投与の経口治療薬に対する患者ニーズの高まりが、慢性疾患管理におけるこのクラスの魅力をさらに高めています。これらの要因が相まって、SGLT2阻害薬は心・腎・代謝疾患との世界の闘いにおける基礎治療薬としての地位を確立しつつあります。

セグメント

適応症（2型糖尿病、心血管、慢性腎臓病、その他）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例

  • Astellas Pharma Inc.
  • AstraZeneca
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Company Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson（Janssen Pharmaceuticals）
  • Kissei Pharmaceutical Co. Ltd.
  • Kowa Company Ltd.
  • Lexicon Pharmaceuticals, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Lupin Limited
  • Mankind Pharma Ltd
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer
  • Sanofi
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Taisho Pharmaceutical Holdings Co.
  • TheracosBio, LLC
  • Torrent Pharmaceuticals Ltd
  • Youngene Therapeutics Inc. Ltd

AIインテグレーション

私たちは、検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32919

Global SGLT2 Inhibitors Market to Reach US$29.5 Billion by 2030

The global market for SGLT2 Inhibitors estimated at US$18.4 Billion in the year 2024, is expected to reach US$29.5 Billion by 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Type 2 Diabetes, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$15.5 Billion by the end of the analysis period. Growth in the Cardiovascular segment is estimated at 8.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.8 Billion While China is Forecast to Grow at 7.9% CAGR

The SGLT2 Inhibitors market in the U.S. is estimated at US$4.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.7 Billion by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global SGLT2 Inhibitors Market - Key Trends & Drivers Summarized

Is Expanding Therapeutic Scope Transforming the Market Landscape for SGLT2 Inhibitors?

The global market for SGLT2 inhibitors is undergoing a major transformation, moving far beyond its original focus on glycemic control in type 2 diabetes. What began as a novel class of antidiabetic agents has now evolved into a cornerstone therapy in cardio-renal-metabolic care. Clinical trials over the last few years have consistently demonstrated that SGLT2 inhibitors such as empagliflozin, dapagliflozin, and canagliflozin deliver significant cardiovascular and renal protective effects independent of their blood glucose-lowering abilities. As a result, these drugs are increasingly being prescribed not only for type 2 diabetes but also for heart failure with reduced ejection fraction (HFrEF), chronic kidney disease (CKD), and more recently, heart failure with preserved ejection fraction (HFpEF). Regulatory bodies across the globe have responded by expanding approved indications, which is dramatically broadening the patient population eligible for these therapies. This shift marks a key inflection point in the market, as endocrinologists, cardiologists, and nephrologists begin to co-manage patients using a shared pharmacological tool. The repositioning of SGLT2 inhibitors as multi-disease agents is significantly boosting their clinical value, healthcare system relevance, and long-term market sustainability.

Can Real-World Evidence and Guideline Inclusion Propel Mainstream Adoption?

One of the most powerful drivers behind the widespread adoption of SGLT2 inhibitors is the robust body of real-world evidence and major endorsements from global clinical guidelines. Organizations such as the American Diabetes Association (ADA), European Society of Cardiology (ESC), Kidney Disease: Improving Global Outcomes (KDIGO), and the American College of Cardiology (ACC) have rapidly incorporated SGLT2 inhibitors into their treatment protocols-not only for glucose control but as first-line therapy for heart failure and CKD, even in patients without diabetes. This cross-specialty acceptance is propelling greater confidence among prescribers, leading to earlier initiation and broader use across patient profiles. Additionally, large-scale outcomes studies continue to reinforce the drug class’s benefits in reducing hospitalization for heart failure, slowing progression of kidney disease, and lowering cardiovascular mortality. These findings have been instrumental in convincing payers and formulary committees to expand reimbursement, especially in markets with value-based healthcare models. The growing repository of post-marketing surveillance data and patient registries is further validating the drugs' safety profiles, helping to dispel concerns around side effects such as diabetic ketoacidosis or genitourinary infections. This strong evidence-based foundation is making SGLT2 inhibitors one of the most rapidly adopted therapeutic classes in recent years.

Are Market Dynamics and Competitive Expansion Driving Innovation in SGLT2-Based Therapies?

The commercial success of first-generation SGLT2 inhibitors has sparked a wave of R&D and competitive activity, with pharmaceutical companies racing to extend the clinical and market footprint of the drug class. The emergence of combination therapies-such as SGLT2 inhibitors paired with DPP-4 inhibitors or GLP-1 receptor agonists-is opening new avenues for integrated diabetes and metabolic disorder management. At the same time, next-generation molecules with dual or triple inhibitory activity (e.g., SGLT1/SGLT2 inhibitors) are being developed to enhance efficacy and expand therapeutic targets. Companies are also exploring novel delivery formats, extended-release formulations, and co-formulated pills to improve patient adherence and convenience. Competitive differentiation is becoming crucial as more players enter the space, particularly in generics and biosimilars as key patents begin to expire. In addition, strategic partnerships, licensing deals, and co-marketing arrangements are on the rise, as firms look to strengthen market positioning and regional access. Geographic expansion into underserved markets-particularly in Asia-Pacific, Latin America, and the Middle East-is another key strategy, enabled by growing awareness of chronic disease prevalence and improvements in diagnostic infrastructure. As the competitive field becomes more sophisticated, innovation and market agility are defining the next growth phase for the SGLT2 inhibitors category.

What’s Fueling the Rapid Growth of the SGLT2 Inhibitors Market?

The growth in the SGLT2 inhibitors market is driven by several factors directly tied to evolving clinical guidelines, expanding indications, and healthcare infrastructure trends. First, the shift from glucose-centric prescribing to a broader focus on cardiovascular and renal protection is significantly increasing the number of eligible patients. Second, strong support from international guidelines is driving adoption across multiple specialties, making these drugs a go-to therapy for cardiologists and nephrologists as well as endocrinologists. Third, the growing global burden of type 2 diabetes, heart failure, and chronic kidney disease is expanding the need for therapies that offer multi-organ protection and long-term outcomes. Fourth, pharmaceutical innovation is extending the life cycle of the drug class through combination therapies, expanded indications, and next-generation molecules. Fifth, improved physician awareness and education programs are encouraging earlier initiation and better adherence. Sixth, payer willingness to reimburse for SGLT2 inhibitors in high-risk patients is supporting access, especially in regions with value-based care models. Seventh, digital health integration is enabling better monitoring and long-term tracking of therapy outcomes, which is helping demonstrate real-world value. Lastly, growing patient demand for oral, once-daily therapies with proven protective benefits is reinforcing the class’s appeal in chronic disease management. Together, these drivers are establishing SGLT2 inhibitors as a foundational therapy in the global fight against cardio-renal-metabolic disorders.

SCOPE OF STUDY:

The report analyzes the SGLT2 Inhibitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 39 Featured) -

  • Astellas Pharma Inc.
  • AstraZeneca
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Company Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Kissei Pharmaceutical Co. Ltd.
  • Kowa Company Ltd.
  • Lexicon Pharmaceuticals, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Lupin Limited
  • Mankind Pharma Ltd
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer
  • Sanofi
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Taisho Pharmaceutical Holdings Co.
  • TheracosBio, LLC
  • Torrent Pharmaceuticals Ltd
  • Youngene Therapeutics Inc. Ltd

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • SGLT2 Inhibitors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Diabetes and Heart Failure Prevalence Throws the Spotlight on SGLT2 Inhibitors as a Dual-Benefit Therapy
    • Expanding Evidence Base in Cardiovascular and Renal Outcomes Propels Growth Beyond Glycemic Control
    • Inclusion in Clinical Guidelines Strengthens the Business Case for Early Adoption and Prescribing Confidence
    • Growing Focus on Integrated Cardio-Renal-Metabolic Care Expands Addressable Market Opportunity
    • Increased R&D Activity and Pipeline Expansion Accelerate Demand for Combination Therapies Involving SGLT2 Inhibitors
    • Real-World Evidence and Post-Marketing Data Drive Adoption Through Demonstrated Long-Term Safety and Efficacy
    • Rising Healthcare Costs Spur Growth in Cost-Effective, Outcome-Driven Therapeutics Like SGLT2 Inhibitors
    • Growing Acceptance in Primary Care Settings Enhances Prescriber Base and Sustains Market Growth
    • Shift Toward Oral Therapies in Chronic Disease Management Drives Preference for SGLT2 Inhibitor Class
    • Increasing Awareness Among Patients and Advocacy Groups Throws the Spotlight on the Need for Holistic Disease Management
    • Focus on Personalized Medicine and Risk Stratification Drives Tailored Use of SGLT2 Inhibitors Across Patient Cohorts
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World SGLT2 Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for SGLT2 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for SGLT2 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Type 2 Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Type 2 Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Type 2 Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chronic Kidney Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chronic Kidney Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Chronic Kidney Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • SGLT2 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • SGLT2 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • SGLT2 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • SGLT2 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for SGLT2 Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for SGLT2 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • SGLT2 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • SGLT2 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • SGLT2 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Rest of Europe 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • SGLT2 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Asia-Pacific 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of World 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of World 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION